Clinical Trials Browser

Neoplasms, Neuroblastoma

NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Phase 1 Terminated

50 enrolled

GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05429502 2025-10-10

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Phase 1 Terminated

12 enrolled

CNSSarcoma

Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma

NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Phase 1 Terminated

122 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

33 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1 Terminated

241 enrolled

DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

6 enrolled

Breast

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast

Breast Neoplasms

NCT04657679 2024-11-26

LEANORA

Phase 4 Terminated

21 enrolled 19 charts

Breast

Breast Neoplasms

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

3 enrolled

Tumor-Agnostic

Neoplasms

NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Phase 1 Terminated

199 enrolled

Breast

Advanced or Metastatic ER+ Breast Cancer

NCT02414724 2022-07-25

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Terminated

10 enrolled

Lymphoid

Lymphoma

NCT03905343 2021-06-16

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Phase 3 Terminated

25 enrolled

Breast

Breast Neoplasms

NCT02703571 2020-12-21

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Phase 1 Terminated

95 enrolled

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT02607124 2020-11-05

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

Phase 1/2 Terminated

11 enrolled 10 charts

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT03050398 2020-05-28

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Phase 3 Terminated

8 enrolled 4 charts

BreastEndocrine

Breast Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02429089 2020-01-09

CETLEE011

Phase 1 Terminated

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT01747876 2019-11-22

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Phase 1 Terminated

32 enrolled 14 charts

CNS

Neuroblastoma

NCT03179956 2019-02-25

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Phase EARLY_PHASE1 Terminated

1 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01919229 2016-01-01

MONALEESA-1

Phase 2 Terminated

14 enrolled 7 charts

Breast

Breast Neoplasms

Clinical Trials

NEPENTHE

(VELA) Study of BLU-222 in Advanced Solid Tumors

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

LEANORA

TAILOR

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

CETLEE011

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

MONALEESA-1